Core Viewpoint - Northeast Pharmaceutical is enhancing shareholder engagement through a promotional event for its new beauty products, aiming to showcase its latest achievements in the health sector and establish a long-term shareholder return mechanism [1][2] Group 1: Shareholder Engagement Activities - The company plans a shareholder reward event from December 25 to December 28, 2025, to help shareholders understand its new beauty products [1] - Eligible shareholders must hold at least 500 shares as of December 8, 2025, and can participate in the event to receive exclusive offers [1] - Shareholders will enjoy a "buy 1 get 4" promotion along with a 10% discount on the total purchase, enhancing the value of their investment [1] Group 2: Business Development in Health Sector - Northeast Pharmaceutical is focusing on the health sector, launching the functional skincare brand "Qifangyuan" to integrate skin health with pharmaceutical technology [2] - The brand leverages the company's national-level technology center and collaborates with research institutes in Shenyang, Beijing, and Shanghai to create a coordinated R&D matrix [2] - The company is expanding into the food and health sector with products like medicinal biscuits, aiming to meet diverse health needs and strengthen its health product matrix [2]

Core Viewpoint - Northeast Pharmaceutical is focusing on market trends, leveraging its two core sales segments, raw materials and formulations, to achieve significant results and ensure stable performance for the company [1] Raw Material Segment - Northeast Pharmaceutical is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan/Korea, with market share increasing year by year [2] - The raw material sales company demonstrated strong market capabilities in Q4, with profits exceeding planned targets for two consecutive months in October and November, particularly in November [2] - Key products such as Vitamin C and L-Carnitine exceeded sales targets, while other products like Amantadine and Piracetam also performed well, enhancing the product matrix's competitiveness [2] - The company actively participated in major industry exhibitions to connect with core customer needs and adjust market strategies based on competitor insights [2][3] Formulation Segment - Northeast Pharmaceutical's formulation products rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [4] - The formulation sales company is focusing on maintaining and expanding the market competitiveness of key products, with systematic planning for products like Gut Health and Pain Relief tablets [4] - Efficient execution and collaboration among teams have led to achieving monthly performance targets, providing confidence for year-end goals [4][5] Expansion into New Fields - In Q4, Northeast Pharmaceutical made significant strides in the health sector by launching new products such as health biscuits and advancing the development of additional health-oriented snacks [6] - The company is exploring the beauty sector with functional skincare products, leveraging its pharmaceutical-grade standards in product development [6] - The company aims to optimize its health product matrix and explore comprehensive health services, creating new growth points [6]

Core Insights - The company is focusing on market trends, with its two core sales segments, raw materials and formulations, playing a significant role in stabilizing performance and achieving important results in market penetration [1][2] - The company is actively expanding in the health sector, launching new products that contribute to comprehensive health services, providing confidence and direction for future work [1][4] Raw Material Segment - The company is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan, with market share increasing year by year [1][2] - In Q4, the raw material sales company demonstrated strong market capabilities, exceeding profit targets in October and November, with notable performance in November [1][2] - Key products such as Vitamin C and L-Carnitine significantly outperformed sales targets, indicating a strengthening product matrix [1][2] Market Expansion and Management - The raw material sales company has actively participated in major industry exhibitions to engage with core customers and align market orders, while also monitoring industry trends and competitor dynamics [2] - Internal management has been enhanced, with a focus on accountability and improving business capabilities, leading to effective collaboration across departments [2] Formulation Segment - The company has several formulation products that rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [3] - A systematic approach has been adopted to boost sales of key products, with effective execution leading to monthly performance improvements [3] New Product Development - In Q4, the company made significant strides in the health sector by launching new products such as health-oriented biscuits, while also developing additional products to meet diverse health needs [4] - The company is leveraging its experience in R&D and quality control to explore the health food sector, including functional skincare products that integrate pharmaceutical technology [4][5] Strategic Focus - The company aims to leverage its comprehensive advantages in innovation, resource allocation, and market positioning to optimize its health product matrix and explore new growth points in the health sector [5]

Core Insights - Northeast Pharmaceutical, a subsidiary of Liaoning Fangda Group, is focusing on expanding its business in the pharmaceutical and health sectors through three key initiatives: drug research and innovation, development of health food products, and entry into the beauty industry with functional skincare products [2][3]. Group 1: Pharmaceutical Innovation - The company views research and innovation as its "lifeline" and has established a robust R&D system, successfully launching over 20 new raw materials and formulations in recent years [3]. - The recent approval of the DC-TY0801 injection for clinical trials marks a significant advancement in the company's oncology treatment portfolio, specifically targeting EGFRvIII positive recurrent or progressive high-grade glioma [3]. - The company is also expanding its pipeline with multiple tumor-targeted cell therapy products, enhancing its capabilities in the healthcare service sector [3]. Group 2: Health Food Development - Northeast Pharmaceutical is tapping into the health food market by launching a series of health-oriented biscuits, including products made from traditional Chinese medicinal ingredients [4]. - The biscuits are developed in collaboration with local universities, ensuring adherence to national food safety standards and scientific formulation [4][5]. - The product line includes various flavors designed to meet different health needs, showcasing the integration of traditional health concepts with modern food technology [4][5]. Group 3: Expansion into Beauty Industry - The company has launched a functional skincare brand, "Qifangyuan," which combines pharmaceutical standards with skincare innovation [6]. - The skincare products are developed using pharmaceutical-grade raw materials and undergo rigorous safety and efficacy testing [6]. - This move is part of a broader strategy to diversify and meet the growing demand for comprehensive health services, leveraging the company's expertise in pharmaceuticals [6].